Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.

Johannes P D SchultheissEelco C BrandEvert LamersWillemijn C M van den BergFiona D M van SchaikBas OldenburgHerma H Fidder

Published in: Alimentary pharmacology & therapeutics (2019)

Drug persistence of anti-TNF-α therapy is lower in females as compared to males, mainly because of higher rates of side effects in females. Understanding the sex specific differences in effectiveness and safety of anti-TNF-α compounds can aid physicians in clinical decision-making.

Keyphrases

rheumatoid arthritis
patients with inflammatory bowel disease
decision making
primary care
emergency department
cell therapy
bone marrow
adverse drug
smoking cessation
replacement therapy